Autopsy report · NCT07805538

Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy

“funding issues and poor accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Fudan University

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Standard Boost.; Boost Omission

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  “Low Accrual, Funding” (87% match in meaning)
• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
  “Lack of funding and slow accrual” (86% match in meaning)
• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
  “Low accrual/Loss of funding” (85% match in meaning)
• Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
  “Slow accrual and lack of funding” (84% match in meaning)
• PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
  “funding issues” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.